MARKED-UP COPY

Claims:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 is selected from hydrogen, C_{1-4}-alkyl, cyano, $-COR^3$, $-CONR^3R^4$ and heteroaryl, wherein

(a) said heteroaryl is optionally substituted with one more substituents independently selected from halogen, hydroxy, cyano, nitro, C_{1-6}-alkyl, C_{3-5}-cycloalkyl, C_{1-4}-alkoxy, fluoro-C_{1-6}-alkyl, fluoro-C_{1-4}-alkoxy, C_{1-4}-alkoxy-C_{1-4}-alkyl, fluoro-C_{1-4}-alkoxy-C_{1-4}-alkyl, C_{6-10}-aryl, heteroaryl, $-NR^{5A}R^{5B}$, $-C_{1-4}$-alkyl-$NR^{5A}R^{5B}$, $-NR^4C(O)O$-C_{1-4}-alkyl, $-NR^4C(O)$-C_{1-4}-alkyl, $-NR^4C(O)O$-fluoro-C_{1-4}-alkyl, $-NR^4C(O)$-fluoro-C_{1-4}-alkyl, $-NR^4C(O)NR^{5A}R^{5B}$, $-C(O)NR^{5A}R^{5B}$, $-C(O)R^4$, $-C(O)OR^4$, $-NR^4S(O)_2$-C_{1-4}-alkyl and $-NR^4S(O)_2$-fluoro-C_{1-4}-alkyl, and

(b) said C_{1-4}-alkyl is optionally substituted with one or more substituents independently selected from fluorine, hydroxyl and C_{1-4}-alkoxy;

X is selected from radicals of formulae (A)-(F) inclusive, any of which being optionally substituted with one more substituents independently selected from halogen, cyano, nitro, C_{1-4}-alkyl, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl and fluoro-C_{1-4}-alkoxy, wherein the bond marked * is attached to R^1 and the bond marked ** is attached to Y;



(A) (B) (C)



(D) (E) (F)

Y is selected from radicals of formulae (H), (J), (K), (L) and (M) any of which is optionally substituted with one more substituents independently selected from fluorine, hydroxyl, C_{1-4}-

MARKED-UP COPY

alkyl, a divalent C_{1-4}-alkylene radical which forms a bridge between ring carbons of said homopiperazine or piperazine, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl , a divalent fluoro-C_{1-4}-alkylene radical which forms a bridge between ring carbons of said homopiperazine or piperazine and fluoro-C_{1-4}-alkoxy, wherein the bond marked * is attached to X and the bond marked ** is attached to R^2;



(H) (J) (K) (L) (M)

and n and m are each independently 1 or 2, and R^{20} is hydrogen, or C_{1-4}-alkyl;

R^2 is selected from radicals of formulae (N)-(S) inclusive, any of which is optionally substituted with one more substituents independently selected from fluorine, hydroxyl, C_{1-4}-alkyl, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl and fluoro-C_{1-4}-alkoxy, wherein the bond marked * is attached to Y;



(N) (O) (P) (Q) (R) (S)

and o and p are each independently 1 or 2, and W is O or NR^9;

R^3 is selected from hydrogen, C_{1-6}-alkyl, C_{3-5}-cycloalkyl, C_{3-5}-cycloalkyl-C_{1-4}-alkyl, heterocyclyl, heterocyclyl-C_{1-4}-alkyl, C_{6-10}-aryl, heteroaryl, C_{6-10}-aryl-C_{1-4}-alkyl and heteroaryl-C_{1-4}-alkyl, wherein

(i) said C_{1-6}-alkyl, C_{3-5}-cycloalkyl, heterocyclyl or the heterocyclyl part of said heterocyclyl-C_{1-4}-alkyl, or the C_{1-6}-alkyl part of said heterocyclyl-C_{1-4}-alkyl, C_{6-10}-aryl-C_{1-4}-alkyl or heteroaryl-C_{1-4}-alkyl, is optionally substituted with one or more substituents independently selected from fluorine, hydroxy, cyano, C_{1-4}-alkoxy and $NR^{5A}R^{5B}$, and

(ii) said C_{6-10}-aryl or heteroaryl, or the C_{6-10}-aryl part of said C_{6-10}-aryl-C_{1-4}-alkyl or the heteroaryl part of said heteroaryl-C_{1-4}-alkyl, is optionally substituted with one more substituents independently selected from halogen, hydroxy, cyano, nitro, C_{1-4}-alkyl, C_1.

MARKED-UP COPY

$_{4}$-alkoxy, fluoro-C_{1-4}-alkyl, fluoro-C_{1-4}-alkoxy, C_{1-4}-alkoxy-C_{1-4}-alkyl, fluoro-C_{1-4}-alkoxy-C_{1-4}-alkyl, $-NR^{5A}R^{5B}$, C_{1-4}-alkyl-$NR^{5A}R^{5B}$, $-NR^4C(O)O-C_{1-4}$alkyl, $-NR^4C(O)-C_{1-4}$alkyl, $-NR^4C(O)O$-fluoro-C_{1-4}alkyl, $-NR^4C(O)$-fluoro-C_{1-4}alkyl, $-NR^4C(O)NR^{5A}R^{5B}$, $-C(O)NR^{5A}R^{5B}$, $-C(O)R^4$, $-C(O)OR^4$, $-NR^4S(O)_2-C_{1-4}$alkyl and $-NR^4S(O)_2$-fluoro-C_{1-4}alkyl;

R^4, R^{5A} and R^{5B} are each independently selected from hydrogen, C_{1-4}-alkyl and fluoro-C_{1-4}-alkyl,

or

R^{5A} and R^{5B} together with the nitrogen atom to which they are bound, form a 4- to 7-membered saturated heterocyclic ring or a heteroaryl ring, said ring being optionally substituted with one or more substituents independently selected from fluorine, hydroxyl, C_{1-4}-alkyl, fluoro-C_{1-4}-alkyl and C_{1-4}-alkoxy,

or

R^3 and R^4, together with the nitrogen atom to which they are bound, form a 4- to 7-membered saturated heterocyclic ring or a heteroaryl ring, said ring being optionally substituted with one or more substituents independently selected from fluorine, hydroxyl, C_{1-4}-alkyl, fluoro-C_{1-4}-alkyl and C_{1-4}-alkoxy; and

R^6 is selected from C_{1-6}-alkyl, C_{3-5}-cycloalkyl, C_{3-5}-cycloalkyl-C_{1-4}-alkyl, heterocyclyl, heterocyclyl-C_{1-4}-alkyl, C_{6-10}-aryl-C_{1-4}-alkyl and C_{6-10}-aryl, wherein

(iii) said C_{1-6}-alkyl, C_{3-5}-cycloalkyl, heterocyclyl, or the C_{1-6}-alkyl part of said heterocyclyl-C_{1-4}-alkyl or C_{6-10}-aryl-C_{1-4}-alkyl, or the heterocyclyl part of said heterocyclyl-C_{1-4}-alkyl is optionally substituted with one or more substituents independently selected from fluorine, hydroxyl and C_{1-4}-alkoxy, and

(iv) said C_{6-10}-aryl or the C_{6-10}-aryl part of said C_{6-10}-aryl-C_{1-4}-alkyl is optionally substituted with one more substituents independently selected from halogen, hydroxy, cyano, nitro, C_{1-4}-alkyl, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl, fluoro-C_{1-4}-alkoxy, C_{1-4}-alkoxy-C_{1-4}-alkyl and fluoro-C_{1-4}-alkoxy-C_{1-4}-alkyl;

R^7 is selected from C_{1-6}-alkyl, C_{3-5}-cycloalkyl, C_{3-5}-cycloalkyl-C_{1-4}-alkyl, heterocyclyl, heterocyclyl-C_{1-4}-alkyl, C_{6-10}-aryl-C_{1-4}-alkyl and C_{6-10}-aryl and $-NR^{10A}R^{10B}$, wherein

MARKED-UP COPY

(v) said C_{1-6}-alkyl, C_{3-5}-cycloalkyl, heterocyclyl, or the C_{1-6}-alkyl part of said heterocyclyl-C_{1-4}-alkyl or C_{6-10}-aryl-C_{1-4}-alkyl, or the heterocyclyl part of said heterocyclyl-C_{1-4}-alkyl is optionally substituted with one or more substituents independently selected from fluorine, hydroxyl and C_{1-4}-alkoxy, and

(vi) said C_{6-10}-aryl or the C_{6-10}-aryl part of said C_{6-10}-aryl-C_{1-4}-alkyl is optionally substituted with one more substituents independently selected from halogen, hydroxy, cyano, nitro, C_{1-4}-alkyl, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl, fluoro-C_{1-4}-alkoxy, C_{1-4}-alkoxy-C_{1-4}-alkyl and fluoro-C_{1-4}-alkoxy-C_{1-4}-alkyl;

R^{8A}, R^{8B} and R^9 are each independently selected from hydrogen, C_{3-5}-cycloalkyl, C_{1-6}-alkyl, and C_{6-10}-aryl-C_{1-4}-alkyl wherein any alkyl residue or cycloalkyl or C_{6-10}-aryl ring system is optionally substituted with one or more substituents independently selected from halogen, hydroxyl and C_{1-4}-alkoxy,

or

R^{8A} and R^{8B}, together with the nitrogen atom to which they are bound, form a 4- to 7-membered saturated heterocyclic ring which is optionally fused to a C_{6-10}-aryl or heteroaryl ring system, the 4- to 7-membered saturated heterocyclic ring or the C_{6-10}-aryl or heteroaryl ring systems being optionally substituted with one or more substituents independently selected from halogen, hydroxyl, C_{1-4}-alkyl, fluoro-C_{1-4}-alkyl and C_{1-4}-alkoxy, and

R^{10A} and R^{10B} are each independently selected from hydrogen and C_{1-6}-alkyl, wherein said C_{1-6}-alkyl is optionally substituted with one or more substituents independently selected from fluorine, hydroxyl and C_{1-4}-alkoxy,

or

R^{10A} and R^{10B}, together with the nitrogen atom to which they are bound, form a 4- to 7-membered saturated heterocyclic ring or a heteroaryl ring, optionally substituted with one or more substituents independently selected from fluorine, hydroxyl, C_{1-4}-alkyl, fluoro-C_{1-4}-alkyl and C_{1-4}-alkoxy; **provided that**

when Y is a piperazine of formula (H) wherein n = 1, then R^2 is not piperidine wherein p = 1, and o = 2, and

MARKED-UP COPY

when Y is a piperazine of formula (H) wherein n = 1 then R^2 is not an alkyl amino of formula (S).

2. A compound as claimed in claim 1 wherein R^1 is $CONR^3R^4$ or heteroaryl wherein said heteroaryl is optionally substituted with one more substituents independently selected from halogen, cyano, C_{1-6}-alkyl, C_{3-5}-cycloalkyl, C_{1-4}-alkoxy, fluoro-C_{1-6}-alkyl, fluoro-C_{1-4}-alkoxy and heteroaryl.

3. A compound as claimed in claim 2 wherein R^1 is heteroaryl selected from benzoxazolyl, indolyl, azaindolyl, imidazolyl, benzimidazolyl, oxazolyl, oxadiazolyl, tetrazolyl, any of which being optionally substituted as specified in claim 1 for R^1 when heteroaryl.

4. A compound as claimed in claim 1 wherein R^1 is $CONR^3R^4$ wherein R^4 is hydrogen or methyl.

5. A compound as claimed in claim 4 wherein R^3 is tetrahydropyranyl, isopropylmethyl, tetrahydropyranylmethyl, imidazolylethyl, methoxyethyl, N-methylimidazolylmethyl, tetrahydrofuranylmethyl, 1-fluorethyl, oxazolylmethyl, pyridylmethyl, 2,2-difluoromethyl, tetrahydrofuranyl, methyl, ethyl, n- or iso-propyl, n-sec-or tert-butyl, cyclopropyl, hydroxyethyl, cyanoethyl, phenyl, , chlorophenyl, methoxyphenyl, methylphenyl, hydroxyphenyl, thiazoloylmethyl, indolyl, methoxypropyl, tetrahydroisoquinolinyl, furylmethylpyridylethyl, thiazolyl, cyclopropylmethyl.

6. A compound according to claim 4 wherein R^3 is pyridyl optionally substituted with one or more substituents selected from halogen, C_{1-4}-alkyl, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl.

7. A compound according to claim 4 where R^3 is 4-pyridyl optionally substituted with one or more methyl groups.

8. A compound as claimed in any of the preceding claims wherein X is a 2,6-pyridyl radical of formula (A).

9. A compound as claimed in any of the preceding claims wherein Y is a homopiperazine radical of formula (H) when n is 2, optionally substituted with one more substituents independently selected from fluorine, hydroxyl, C_{1-4}-alkyl, a divalent C_{1-4}-alkylene radical

MARKED-UP COPY

which forms a bridge between ring carbons of said homopiperazine or piperazine, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl or a divalent fluoro-C_{1-4}-alkylene radical which forms a bridge between ring carbons of said homopiperazine or piperazine, and fluoro-C_{1-4}-alkoxy.

10. A compound as claimed in any one of claims 1 to 8 wherein Y is a piperazine radical of formula (H) when n is 1, optionally substituted with one more substituents independently selected from fluorine, hydroxyl, C_{1-4}-alkyl, a divalent C_{1-4}-alkylene radical which forms a bridge between ring carbons of said homopiperazine or piperazine, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl or a divalent fluoro-C_{1-4}-alkylene radical which forms a bridge between ring carbons of said homopiperazine or piperazine, and fluoro-C_{1-4}-alkoxy.

11. A compound as claimed in claim 9 wherein R^2 is a 4-piperidine radical of formula (N) wherein o is 2 and p is 1, a 4-azepine radical of formula (N) wherein o is 2 and p is 2, a 1,4-cyclohexyl radical of formula (R) or a -CH_2morphilin-3-yl radical of formula (Q) wherein W is O, said 4-piperidine, 4-azepine, 1,4-cyclohexyl and -CH_2morphilin-3-yl radicals being optionally substituted with one more substituents independently selected from fluorine, hydroxyl, C_{1-4}-alkyl, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl and fluoro-C_{1-4}-alkoxy.

12. A compound as claimed in claim 10 wherein R^2 is a 4-azepine radical of formula (N) wherein o is 2 and p is 2, a 1,4-cyclohexyl radical of formula (R) or a -CH_2morphilin-3-yl radical of formula (Q) wherein W is O, said a 4-azepine, 1,4-cyclohexyl and -CH_2morphilin-3-yl radicals being optionally substituted with one more substituents independently selected from fluorine, hydroxyl, C_{1-4}-alkyl, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl and fluoro-C_{1-4}-alkoxy.

13. A compound as claimed in any of the preceding claims wherein R^6 is selected from hydrogen, halogen, C_{1-6}-alkyl, C_{1-6}-fluoroalkyl, C_{1-4}-alkoxy, C_{1-2}-alkoxy-C_{1-4}alkyl, C_{3-5}-cycloalkyl, C_{3-5}-fluorocycloalkyl, benzyl, alpha-methyl-benzyl, and benzyl or alpha-methyl-benzyl either of which being optionally ring-substituted by one or two substituents selected from halogen, C_{1-4}-alkyl, C_{1-4}-alkoxy,

14. A compound as claimed in claim 1 having formula (IA):

MARKED-UP COPY



(IA)

wherein R^6 is as defined in claim 1, and R^{21} and R^{22} are independently selected from hydrogen, halogen, C_{1-6} alkyl, C_{1-6} fluoroalkyl, C_{1-4} alkoxy, C_{1-2} alkoxy- C_{1-4} alkyl, C_{3-5} cycloalkyl, C_{3-5} fluorocycloalkyl, benzyl, alpha methyl-benzyl, and benzyl or alpha methyl-benzyl either of which being optionally ring-substituted by one or two substituents selected from halogen, C_{1-4} alkyl, or C_{1-4} alkoxy;

15. A compound as claimed in claim 12 wherein R^{21} and R^{22} are independently selected from hydrogen and methyl, and R^6 is isopropyl.

16. A compound as claimed in any of the preceding claims having the structural formula of any of the examples.

17. A pharmaceutical composition comprising a compound as claimed in any of the preceding claims, together with one or more pharmaceutically acceptable carriers and/or excipients.

18. The use of a compound as claimed in any of claims 1 to 16 in the preparation of a composition for treatment of a condition responsive to the reduction of CXCR4 mediated activity.

14. A method of treatment of a condition responsive to the reduction of CXCR4 mediated activity in a subject, comprising administrating to the subject an amount of a compound as claimed in any of claims 1 to 11 effective to reduce such CXCR4 mediated activity.

15. The use as claimed in claim 13 or a method as claimed in claim 14, wherein the condition is cancer including cancers of the haematopoietic system such as multiple myeloma and non-Hodgkin's lymphoma, non-small cell lung, breast and neuroblastoma, cancer metastasis, HIV/AIDS, neuropathy, HIV-related neuropathy, pain, inflammation, brain inflammation, neurodegeration, cognitive degeneration, diabetic retinopathy, age related macular degeneration, retinal neo-vascularisation, and viral infections.

MARKED-UP COPY

16. The use of a compound as claimed in any of claims 1 to 11 in an apheresis procedure for promoting release and mobilisation of stem cells, including haematopoietic and non-haematopoietic stem cells and progenitor stem cells prior to harvesting.

17. The use of a compound as claimed in any of claims 1 to 11 and GCSF in an apheresis procedure for promoting release and mobilisation of stem cells, including haematopoietic and non-haematopoietic stem cells and progenitor stem cells prior to harvesting.

18. The use according to claim 17 wherein the said apheresis procedure is implemented prior to treatment of a subject by chemotherapy or radiotherapy, for reducing chemotherapy- or radiotherapy-induced leukopenia.

19. The use according to claim 15 wherein the said compound is administered as an adjunct to chemotherapy or radiotherapy to sensitize tumours to such chemotherapy or radiotherapy.

20. The use according to claim 15 for inhibition of neo-vascularisation, angiogenesis, or vasculogenesis.

MARKED-UP COPY

Proposed Amendment filed in response to 1st Office action in Singapore

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 is selected from ~~hydrogen,~~ C_{1-4}-alkyl, cyano, $-COR^3$, $-CONR^3R^4$ and heteroaryl, wherein

(a) said heteroaryl is optionally substituted with one more substituents independently selected from halogen, hydroxy, cyano, nitro, C_{1-6}-alkyl, C_{3-5}-cycloalkyl, C_{1-4}-alkoxy, fluoro-C_{1-6}-alkyl, fluoro-C_{1-4}-alkoxy, C_{1-4}-alkoxy-C_{1-4}-alkyl, fluoro-C_{1-4}-alkoxy-C_{1-4}-alkyl, C_{6-10}-aryl, heteroaryl, $-NR^{5A}R^{5B}$, $-C_{1-4}$-alkyl-$NR^{5A}R^{5B}$, $-NR^4C(O)O-C_{1-4}$-alkyl, $-NR^4C(O)-C_{1-4}$-alkyl, $-NR^4C(O)O$-fluoro-C_{1-4}-alkyl, $-NR^4C(O)$-fluoro-C_{1-4}-alkyl, $-NR^4C(O)NR^{5A}R^{5B}$, $-C(O)NR^{5A}R^{5B}$, $-C(O)R^4$, $-C(O)OR^4$, $-NR^4S(O)_2-C_{1-4}$-alkyl and $-NR^4S(O)_2$-fluoro-C_{1-4}-alkyl, and

(b) said C_{1-4}-alkyl is optionally substituted with one or more substituents independently selected from fluorine, hydroxyl and C_{1-4}-alkoxy;

X is selected from radicals of formulae (A)-(F) inclusive, any of which being optionally substituted with one more substituents independently selected from halogen, cyano, nitro, C_{1-4}-alkyl, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl and fluoro-C_{1-4}-alkoxy, wherein the bond marked * is attached to R^1 and the bond marked ** is attached to Y:



(A) (B) (C)



(D) (E) (F)

Y is selected from radicals of formulae (H), (J), (K), and (M) any of which is optionally substituted with one more substituents independently selected from fluorine, hydroxyl, C_{1-4}-

alkyl, a divalent C_{1-4}-alkylene radical which forms a bridge between ring carbons of said homopiperazine or piperazine, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl , a divalent fluoro-C_{1-4}-alkylene radical which forms a bridge between ring carbons of said homopiperazine or piperazine and fluoro-C_{1-4}-alkoxy, wherein the bond marked * is attached to X and the bond marked ** is attached to R^2:



(H) (J) (K) (M)

and n and m are each independently 1 or 2;

R^2 is selected from radicals of formulae (N)-(~~S~~R) inclusive, any of which is optionally substituted with one more substituents independently selected from fluorine, hydroxyl, C_{1-4}-alkyl, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl and fluoro-C_{1-4}-alkoxy, wherein the bond marked * is attached to Y:



(N) (O) (P) (Q) (R) (S)

and o and p are each independently 1 or 2, and W is O or NR^9;

R^3 is selected from hydrogen, C_{1-6}-alkyl, C_{3-5}-cycloalkyl, C_{3-5}-cycloalkyl-C_{1-4}-alkyl, heterocyclyl, heterocyclyl-C_{1-4}-alkyl, C_{6-10}-aryl, heteroaryl, C_{6-10}-aryl-C_{1-4}-alkyl and heteroaryl-C_{1-4}-alkyl, wherein

(i) said C_{1-6}-alkyl, C_{3-5}-cycloalkyl, heterocyclyl or the heterocyclyl part of said heterocyclyl-C_{1-4}-alkyl, or the ~~C_{1-6}-alkyl~~ C_{1-4}-alkyl part of said heterocyclyl-C_{1-4}-alkyl, C_{6-10}-aryl-C_{1-4}-alkyl or heteroaryl-C_{1-4}-alkyl, is optionally substituted with one or more substituents independently selected from fluorine, hydroxy, cyano, C_{1-4}-alkoxy and –$NR^{5A}R^{5B}$, and

(ii) said C_{6-10}-aryl or heteroaryl, or the C_{6-10}-aryl part of said C_{6-10}-aryl-C_{1-4}-alkyl or the heteroaryl part of said heteroaryl-C_{1-4}-alkyl, is optionally substituted with one more substituents independently selected from halogen, hydroxy, cyano, nitro, C_{1-4}-alkyl, C_{1-}

$_{4}$-alkoxy, fluoro-C_{1-4}-alkyl, fluoro-C_{1-4}-alkoxy, C_{1-4}-alkoxy-C_{1-4}-alkyl, fluoro-C_{1-4}-alkoxy-C_{1-4}-alkyl, $-NR^{5A}R^{5B}$, $-C_{1-4}$-alkyl-$NR^{5A}R^{5B}$, $-NR^{4}C(O)O$-C_{1-4}alkyl, $-NR^{4}C(O)$-C_{1-4}alkyl, $-NR^{4}C(O)O$-fluoro-C_{1-4}alkyl, $-NR^{4}C(O)$-fluoro-C_{1-4}alkyl, $-NR^{4}C(O)NR^{5A}R^{5B}$, $-C(O)NR^{5A}R^{5B}$, -$C(O)R^{4}$, -$C(O)OR^{4}$, $-NR^{4}S(O)_2$-C_{1-4}alkyl and $-NR^{4}S(O)_2$-fluoro-C_{1-4}alkyl;

R^4, R^{5A} and R^{5B} are each independently selected from hydrogen, C_{1-4}-alkyl and fluoro-C_{1-4}-alkyl,

or

R^{5A} and R^{5B} together with the nitrogen atom to which they are bound, form a 4- to 7-membered saturated heterocyclic ring or a heteroaryl ring, said ring being optionally substituted with one or more substituents independently selected from fluorine, hydroxyl, C_{1-4}-alkyl, fluoro-C_{1-4}-alkyl and C_{1-4}-alkoxy,

or

R^3 and R^4, together with the nitrogen atom to which they are bound, form a 4- to 7-membered saturated heterocyclic ring or a heteroaryl ring, said ring being optionally substituted with one or more substituents independently selected from fluorine, hydroxyl, C_{1-4}-alkyl, fluoro-C_{1-4}-alkyl and C_{1-4}-alkoxy; and

R^6 is selected from C_{1-6}-alkyl, C_{3-5}-cycloalkyl, C_{3-5}-cycloalkyl-C_{1-4}-alkyl, heterocyclyl, heterocyclyl-C_{1-4}-alkyl, C_{6-10}-aryl-C_{1-4}-alkyl and C_{6-10}-aryl, wherein

(iii) said C_{1-6}-alkyl, C_{3-5}-cycloalkyl, heterocyclyl, or the ~~C_{1-6}-alkyl~~ C_{1-4}-alkyl part of said heterocyclyl-C_{1-4}-alkyl or C_{6-10}-aryl-C_{1-4}-alkyl, or the heterocyclyl part of said heterocyclyl-C_{1-4}-alkyl is optionally substituted with one or more substituents independently selected from fluorine, hydroxyl and C_{1-4}-alkoxy, and

(iv) said C_{6-10}-aryl or the C_{6-10}-aryl part of said C_{6-10}-aryl-C_{1-4}-alkyl is optionally substituted with one more substituents independently selected from halogen, hydroxy, cyano, nitro, C_{1-4}-alkyl, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl, fluoro-C_{1-4}-alkoxy, C_{1-4}-alkoxy-C_{1-4}-alkyl and fluoro-C_{1-4}-alkoxy-C_{1-4}-alkyl;

R^7 is selected from C_{1-6}-alkyl, C_{3-5}-cycloalkyl, C_{3-5}-cycloalkyl-C_{1-4}-alkyl, heterocyclyl, heterocyclyl-C_{1-4}-alkyl, C_{6-10}-aryl-C_{1-4}-alkyl and C_{6-10}-aryl and
$-NR^{10A}R^{10B}$, wherein

(v) said C_{1-6}-alkyl, C_{3-5}-cycloalkyl, heterocyclyl, or the ~~C_{1-6}-alkyl~~ C_{1-4}-alkyl part of said heterocyclyl-C_{1-4}-alkyl or C_{6-10}-aryl-C_{1-4}-alkyl, or the heterocyclyl part of said heterocyclyl-C_{1-4}-alkyl is optionally substituted with one or more substituents independently selected from fluorine, hydroxyl and C_{1-4}-alkoxy, and

(vi) said C_{6-10}-aryl or the C_{6-10}-aryl part of said C_{6-10}-aryl-C_{1-4}-alkyl is optionally substituted with one more substituents independently selected from halogen, hydroxy, cyano, nitro, C_{1-4}-alkyl, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl, fluoro-C_{1-4}-alkoxy, C_{1-4}-alkoxy-C_{1-4}-alkyl and fluoro-C_{1-4}-alkoxy-C_{1-4}-alkyl;

R^{8A}, R^{8B} and R^9 are each independently selected from hydrogen, C_{3-5}-cycloalkyl,C_{1-6}-alkyl, and C_{6-10}-aryl-C_{1-4}-alkyl wherein any alkyl residue or cycloalkyl or C_{6-10}-aryl ring system is optionally substituted with one or more substituents independently selected from halogen, hydroxyl and C_{1-4}-alkoxy,

or

R^{8A} and R^{8B}, together with the nitrogen atom to which they are bound, form a 4- to 7-membered saturated heterocyclic ring which is optionally fused to a C_{6-10}-aryl or heteroaryl ring system, the 4- to 7-membered saturated heterocyclic ring or the C_{6-10}-aryl or heteroaryl ring systems being optionally substituted with one or more substituents independently selected from halogen, hydroxyl, C_{1-4}-alkyl, fluoro-C_{1-4}-alkyl and C_{1-4}-alkoxy; and

R^{10A} and R^{10B} are each independently selected from hydrogen and C_{1-6}-alkyl, wherein said C_{1-6}-alkyl is optionally substituted with one or more substituents independently selected from fluorine, hydroxyl and C_{1-4}-alkoxy,

or

R^{10A} and R^{10B}, together with the nitrogen atom to which they are bound, form a 4- to 7-membered saturated heterocyclic ring or a heteroaryl ring, optionally substituted with one or more substituents independently selected from fluorine, hydroxyl, C_{1-4}-alkyl, fluoro-C_{1-4}-alkyl and C_{1-4}-alkoxy; **provided that**

when Y is a piperazine of formula (H) wherein n = 1, then R^2 is not piperidine wherein p = 1, and o = 2~~;~~

~~and~~

MARKED-UP COPY

~~when Y is a piperazine of formula (H) wherein n = 1 then R^2 is not an alkyl amino of formula (S).~~

2. A compound as claimed in claim 1 wherein R^1 is $CONR^3R^4$ or heteroaryl wherein said heteroaryl is optionally substituted with one more substituents independently selected from halogen, cyano, C_{1-6}-alkyl, C_{3-5}-cycloalkyl, C_{1-4}-alkoxy, fluoro-C_{1-6}-alkyl, fluoro-C_{1-4}-alkoxy and heteroaryl.

3. A compound as claimed in claim 2 wherein R^1 is heteroaryl selected from benzoxazolyl, indolyl, azaindolyl, imidazolyl, benzimidazolyl, oxazolyl, oxadiazolyl, tetrazolyl, any of which being optionally substituted as specified in claim 1 for R^1 when heteroaryl.

4. A compound as claimed in claim 1 wherein R^1 is $CONR^3R^4$ wherein R^4 is hydrogen or methyl.

5. A compound as claimed in claim 4 wherein R^3 is tetrahydropyranyl, isopropylmethyl, tetrahydropyranylmethyl, imidazolylethyl, methoxyethyl, N-methylimidazolylmethyl, tetrahydrofuranylmethyl, 1-fluorothyl, oxazolylmethyl, pyridylmethyl, 2,2-difluoromethyl, tetrahydrofuranyl, methyl, ethyl, n- or iso-propyl, n-sec-or tert-butyl, cyclopropyl, hydroxyethyl, cyanoethyl, phenyl, , chlorophenyl, methoxyphenyl, methylphenyl, hydroxyphenyl, thiazoloylmethyl, indolyl, methoxypropyl, tetrahydroisoquinolinyl, furylmethylpyridylethyl, thiazolyl, cyclopropylmethyl.

6. A compound according to claim 4 wherein R^3 is pyridyl optionally substituted with one or more substituents selected from halogen, C_{1-4}-alkyl, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl.

7. A compound according to claim 4 where R^3 is 4-pyridyl optionally substituted with one or more methyl groups.

8. A compound as claimed in any of the preceding claims wherein X is a 2,6-pyridyl radical of formula (A)

9. A compound as claimed in any of the preceding claims wherein Y is a homopiperazine radical of formula (H) when n is 2, optionally substituted with one more substituents independently selected from fluorine, hydroxyl, C_{1-4}-alkyl, a divalent C_{1-4}-alkylene radical

which forms a bridge between ring carbons of said homopiperazine or piperazine, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl or a divalent fluoro-C_{1-4}-alkylene radical which forms a bridge between ring carbons of said homopiperazine or piperazine, and fluoro-C_{1-4}-alkoxy.

10. A compound as claimed in any one of claims 1 to 8 wherein Y is a piperazine radical of formula (H) when n is 1, optionally substituted with one more substituents independently selected from fluorine, hydroxyl, C_{1-4}-alkyl, a divalent C_{1-4}-alkylene radical which forms a bridge between ring carbons of said homopiperazine or piperazine, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl or a divalent fluoro-C_{1-4}-alkylene radical which forms a bridge between ring carbons of said homopiperazine or piperazine, and fluoro-C_{1-4}-alkoxy.

11. A compound as claimed in claim 9 wherein R^2 is a 4-piperidine radical of formula (N) wherein o is 2 and p is 1, a 4-azepine radical of formula (N) wherein o is 2 and p is 2, a 1,4-cyclohexyl radical of formula (R) or a -CH_2morphilin-3-yl radical of formula (Q) wherein W is O, said 4-piperidine, 4-azepine, 1,4-cyclohexyl and -CH_2morphilin-3-yl radicals being optionally substituted with one more substituents independently selected from fluorine, hydroxyl, C_{1-4}-alkyl, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl and fluoro-C_{1-4}-alkoxy.

12. A compound as claimed in claim 10 wherein R^2 is a 4-azepine radical of formula (N) wherein o is 2 and p is 2, a 1,4-cyclohexyl radical of formula (R) or a -CH_2morphilin-3-yl radical of formula (Q) wherein W is O, said a 4-azepine, 1,4-cyclohexyl and -CH_2morphilin-3-yl radicals being optionally substituted with one more substituents independently selected from fluorine, hydroxyl, C_{1-4}-alkyl, C_{1-4}-alkoxy, fluoro-C_{1-4}-alkyl and fluoro-C_{1-4}-alkoxy.

13. A compound as claimed in any of the preceding claims wherein R^6 is selected from hydrogen, halogen, C_{1-6}-alkyl, C_{1-6} fluoroalkyl, C_{1-4}-alkoxy, C_{1-2}-alkoxy- C_{1-4}alkyl, C_{3-5} cycloalkyl, C_{3-5} fluorocycloalkyl, benzyl, alpha methyl-benzyl, and benzyl or alpha methyl-benzyl either of which being optionally ring-substituted by one or two substituents selected from halogen, C_{1-4}-alkyl, C_{1-4}-alkoxy,

14. A compound as claimed in claim 1 having formula (IA):



(IA)

wherein R^6 is as defined in claim 1, and R^{21} and R^{22} are independently selected from hydrogen, halogen, C_{1-6}-alkyl, C_{1-6} fluoroalkyl, C_{1-4}-alkoxy, C_{1-2}-alkoxy- C_{1-4}alkyl, C_{3-5} cycloalkyl, C_{3-5} fluorocycloalkyl, benzyl, alpha methyl-benzyl, and benzyl or alpha methyl-benzyl either of which being optionally ring-substituted by one or two substituents selected from halogen, C_{1-4}-alkyl, or C_{1-4}-alkoxy,

15. A compound as claimed in claim 12 wherein R^{21} and R^{22} are independently selected from hydrogen and methyl, and R^6 is isopropyl.

16. A compound as claimed in ~~any of the preceding claims having the structural formula of any of the examples.~~claim 1 selected from any one of the group consisting of:

N-(Oxan-4-ylmethyl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;
N-(Oxan-4-yl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;
N-[3-(1H-Imidazol-1-yl)propyl]-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;
N-Ethyl-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;
6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-propylpyridine-2-carboxamide;
N-(2-Methylpropyl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;
N-Butyl-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;
N-(2-Fluoroethyl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;
N-(2,2-Difluoroethyl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;
6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(2,2,2-trifluoroethyl)pyridine-2-carboxamide;
N-Cyclopropyl-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-

carboxamide;

N-(2-Hydroxyethyl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(2-Cyanoethyl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(2-Methoxyethyl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(3-Methoxypropyl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-[2-(Dimethylamino)ethyl]-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-Methyl-N-(2-methylpropyl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-[(3S)-Oxolan-3-yl]-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-[(3R)-Oxolan-3-yl]-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-[(2R)-Oxolan-2-ylmethyl]-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

1-[(6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridin-2-yl)carbonyl]-2,3-dihydro-1H-indole;

2-[(6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridin-2-yl)carbonyl]-1,2,3,4-tetrahydroisoquinoline;

N-Phenyl-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide; N-(2-Hydroxyphenyl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(4-Chlorophenyl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(4-Methoxyphenyl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(4-Methylphenyl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-2-yl)pyridine-2-carboxamide;

6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-3-yl)pyridine-2-carboxamide;

6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(1,3-thiazol-2-yl)pyridine-2-carboxamide;

6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(1,3-thiazol-5-yl)pyridine-2-carboxamide;

6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-2-ylmethyl)pyridine-2-carboxamide;

6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-3-ylmethyl)pyridine-2-carboxamide;

N-Methyl-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-3-ylmethyl)pyridine-2-carboxamide;

6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-ylmethyl)pyridine-2-carboxamide;

N-[(1-Methyl-1H-imidazol-2-yl)methyl]-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(1,3-Oxazol-2-ylmethyl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(1,3-thiazol-2-ylmethyl)pyridine-2-carboxamide;

N-(Furan-2-ylmethyl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(1,3-Oxazol-4-ylmethyl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(1,3-thiazol-4-ylmethyl)pyridine-2-carboxamide;

6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(1,3-thiazol-5-ylmethyl)pyridine-2-carboxamide;

N-(1,3-Oxazol-5-ylmethyl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-[2-(1H-Imidazol-1-yl)ethyl]-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-[2-(pyridin-2-yl)ethyl]pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-1,4-diazepan-1-yl)-N-(oxan-4-ylmethyl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-1,4-diazepan-1-yl)-N-(2,2,2-trifluoroethyl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-1,4-diazepan-1-yl)-N-(3-methylbutyl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-1,4-diazepan-1-yl)-N-(2-methoxyethyl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-1,4-diazepan-1-yl)-N-[(2R)-oxolan-2-ylmethyl]pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-1,4-diazepan-1-yl)-N-(oxan-4-yl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-1,4-diazepan-1-yl)-N-(pyridine-3-yl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-1,4-diazepan-1-yl)-N-(pyridine-4-yl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-1,4-diazepan-1-yl)-N-(pyridine-3-ylmethyl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-1,4-diazepan-1-yl)-N-(pyridine-4-ylmethyl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-1,4-diazepan-1-yl)-N-(1,3-oxazol-2-ylmethyl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-1,4-diazepan-1-yl)-N-(1,3-oxazol-4-ylmethyl)pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{4-[1-(1,3-difluoropropan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-[4-(1-ethylpiperidin-4-yl)-1,4-diazepan-1-yl]pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-[4-(1-propylpiperidin-4-yl)-1,4-diazepan-1-yl]pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-[4-(1-cyclopropylpiperidin-4-yl)-1,4-diazepan-1-yl]pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

6-[4-(1-tert-Butylpiperidin-4-yl)-1,4-diazepan-1-yl]-N-(cyclo propylmethyl)pyridine-2-carboxamide;

6-{4-[1-(Butan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(cyclopropyl methyl)pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{4-[1-(pentan-3-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{4-[1-(1-fluoropropan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{4-[1-(1,1-difluoropropan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-(4-{1-[(2S)-1,1,1-trifluoropropan-2-yl]piperidin-4-yl}-1,4-diazepan-1-yl)pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{4-[1-(4,4,4-trifluorobutan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{4-[1-(2-methoxyethyl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

6-[4-(1-Cyclopentylpiperidin-4-yl)-1,4-diazepan-1-yl]-N-(cyclopropyl methyl)pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{4-[1-(2-fluorocyclopentyl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-(4-{1-[(1R)-1-phenylethyl]piperidin-4-yl}-1,4-diazepan-1-yl)pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-(4-{1-[(1R)-1-(4-fluorophenyl)ethyl]piperidin-4-yl}-1,4-diazepan-1-yl)pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-(4-{1-[(1R)-2,3-dihydro-1H-inden-1-yl]piperidin-4-yl}-1,4-diazepan-1-yl)pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-(4-{1-[(1S)-2,3-dihydro-1H-inden-1-yl]piperidin-4-yl}-1,4-diazepan-1-yl)pyridine-2-carboxamide;

6-(4-{1-[(2R)-Butan-2-yl]piperidin-4-yl}-1,4-diazepan-1-yl)-N-(pyridine-4-yl)pyridine-2-carboxamide;

6-(4-{1-[(2S)-Butan-2-yl]piperidin-4-yl}-1,4-diazepan-1-yl)-N-(pyridine-4-yl)pyridine-2-carboxamide;

6-[4-(1-tert-Butylpiperidin-4-yl)-1,4-diazepan-1-yl]-N-(pyridine-4-yl)pyridine-2-carboxamide;

N-(Pyridin-4-yl)-6-(4-{1-[(2R)-1,1,1-trifluoropropan-2-yl]piperidin-4-yl}-1,4-diazepan-1-yl)pyridine-2-carboxamide;

N-(Pyridin-4-yl)-6-(4-{1-[(2S)-1,1,1-trifluoropropan-2-yl]piperidin-4-yl}-1,4-diazepan-1-yl)pyridine-2-carboxamide;

6-[4-(1-Cyclopentylpiperidin-4-yl)-1,4-diazepan-1-yl]-N-(pyridine-4-yl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-1,4-diazepan-1-yl)-N-(2-methylpyridin-4-yl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-1,4-diazepan-1-yl)-N-(2,6-dimethylpyridin-4-yl)pyridine-2-carboxamide;

N-(2-Methylpyridin-4-yl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(2,6-Dimethylpyridin-4-yl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(3-Methylpyridin-4-yl)-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(Pyridin-3-ylmethyl)-6-(4-{1-[(2S)-1,1,1-trifluoropropan-2-yl]piperidin-4-yl}-1,4-diazepan-1-yl)pyridine-2-carboxamide;

N-(Pyridin-3-ylmethyl)-6-{4-[1-(4,4,4-trifluorobutan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(Pyridin-3-ylmethyl)-6-{4-[1-(1,1,1-trifluoro-2-methylpropan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

6-(4-{1-[(1R)-1-Phenylethyl]piperidin-4-yl}-1,4-diazepan-1-yl)-N-(pyridine-3-ylmethyl)pyridine-2-carboxamide;

N-Butyl-6-(4-{1-[(2S)-1,1,1-trifluoropropan-2-yl]piperidin-4-yl}-1,4-diazepan-1-yl)pyridine-2-carboxamide;

N-(1,3-Thiazol-2-ylmethyl)-6-(4-{1-[(2S)-1,1,1-trifluoropropan-2-yl]piperidin-4-yl}-1,4-diazepan-1-yl)pyridine-2-carboxamide;

1-Methyl-2-(6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-yl)-1H-indole;

1-[1-(Propan-2-yl)piperidin-4-yl]-4-(6-{1H-pyrrolo[3,2-b]pyridine-2-yl}pyridine-2-yl)-1,4-diazepane;

1-[1-(Propan-2-yl)piperidin-4-yl]-4-(6-{1H-pyrrolo[3,2-c]pyridine-2-yl}pyridine-2-yl)-1,4-diazepane;

1-[1-(Propan-2-yl)piperidin-4-yl]-4-(6-{1H-pyrrolo[2,3-c]pyridine-2-yl}pyridine-2-yl)-1,4-diazepane;

1-[1-(Propan-2-yl)piperidin-4-yl]-4-(6-{1H-pyrrolo[2,3-b]pyridine-2-yl}pyridine-2-yl)-1,4-diazepane;

2-(6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-yl)-1H-indole;

1-[1-(Propan-2-yl)piperidin-4-yl]-4-(6-{1H-pyrrolo[2,3-b]pyridine-3-yl}pyridine-2-yl)-1,4-diazepane;

3-(6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-yl)-1H-indole;

2-(6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-yl)-1H-indole-6-carbonitrile;

6-Methoxy-2-(6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-yl)-1H-indole;

5-Methoxy-2-(6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-yl)-1H-indole;

1-(6-{3H-Imidazo[4,5-c]pyridin-2-yl}pyridin-2-yl)-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(4-Methyl-1H-imidazol-2-yl)pyridine-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(4-Ethyl-1H-imidazol-2-yl)pyridine-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[1-(Propan-2-yl)piperidin-4-yl]-4-[6-(4-propyl-1H-imidazol-2-yl)pyridine-2-yl]-1,4-diazepane;

1-{6-[4-(Propan-2-yl)-1H-imidazol-2-yl]pyridine-2-yl}-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(4-Cyclopropyl-1H-imidazol-2-yl)pyridine-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[1-(Propan-2-yl)piperidin-4-yl]-4-{6-[4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine-2-yl}-1,4-diazepane;

1-[6-(4-tert-Butyl-1H-imidazol-2-yl)pyridine-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(4-Phenyl-1H-imidazol-2-yl)pyridine-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(4-Ethyl-1H-imidazol-2-yl)pyridine-2-yl]-4-{1-[(2S)-1,1,1-trifluoropropan-2-yl]piperidin-4-yl}-1,4-diazepane;

1-{1-[(2R)-Butan-2-yl]piperidin-4-yl}-4-[6-(4-ethyl-1H-imidazol-2-yl)pyridine-2-yl]-1,4-diazepane;

1-[6-(4-tert-Butyl-1H-imidazol-2-yl)pyridine-2-yl]-4-(1-tert-butylpiperidin-4-yl)-1,4-diazepane;

1-[6-(4,5-Dimethyl-1H-imidazol-2-yl)pyridine-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(5-Ethyl-4-methyl-1H-imidazol-2-yl)pyridine-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(4,5-Diethyl-1H-imidazol-2-yl)pyridine-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(4-Cyclopropyl-5-methyl-1H-imidazol-2-yl)pyridine-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(4-Cyclopropyl-5-ethyl-1H-imidazol-2-yl)pyridine-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(5-Methyl-4-propyl-1H-imidazol-2-yl)pyridine-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(4-Ethyl-1-methyl-1H-imidazol-2-yl)pyridine-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

N-(Cyclopropylmethyl)-3-methyl-6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

1-[1-(2,3-Dihydro-1H-inden-1-yl)piperidin-4-yl]-4-(1,3-thiazol-2-yl)-1,4-diazepane;

N-(Cyclopropylmethyl)-6-{4-[1-(1-methoxypropan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{4-[1-(oxolan-3-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

6-[4-(1-Benzylpiperidin-4-yl)-1,4-diazepan-1-yl]-N-(cyclopropyl methyl)pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-(4-{1-[(4-fluorophenyl)methyl]piperidin-4-yl}-1,4-diazepan-1-yl)pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-(4-{1-[(2-methylphenyl)methyl]piperidin-4-yl}-1,4-diazepan-1-yl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-1,4-diazepan-1-yl)-N-(cyclopropylmethyl)pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-(4-{1-[(2-methoxyphenyl)methyl]piperidin-4-yl}-1,4-diazepan-1-yl)pyridine-2-carboxamide;

6-(4-{1-[(3-Chlorophenyl)methyl] piperidin-4-yl}-1,4-diazepan-1-yl)-N-(cyclopropylmethyl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chloro-4-fluorophenyl) methyl]piperidin-4-yl}-1,4-diazepan-1-yl)-N-(cyclopropylmethyl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-1,4-diazepan-1-yl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-1,4-diazepan-1-yl)-N-ethylpyridine-2-carboxamide;

N-Butyl-6-(4-{1-[(2-chlorophenyl)methyl]piperidin-4-yl}-1,4-diazepan-1-yl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-1,4-diazepan-1-yl)-N-[3-(1H-imidazol-1-yl)propyl]pyridine-2-carboxamide;

1-Methyl-2-(6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridin-2-yl)-1H-1,3-benzodiazole;

2-(6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-yl)-1H-1,3-benzodiazole;

7-Fluoro-2-(6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-yl)-1H-1,3-benzodiazole;

7-Methyl-2-(6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-yl)-1H-1,3-benzodiazole;

2-(6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-yl)-6-(trifluoromethyl)-1H-1,3-benzodiazole;

5,6-Difluoro-2-(6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-yl)-1H-1,3-benzodiazole;

5,6-Dimethyl-2-(6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-yl)-1H-1,3-benzodiazole;

6-Fluoro-2-(6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-yl)-1H-1,3-benzodiazole;

6-Methyl-2-(6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-yl)-1H-1,3-benzodiazole;

2-(6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-yl)-1H-1,3-benzodiazole-6-carbonitrile;

6-Methoxy-2-(6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-yl)-1H-1,3-benzodiazole;

2-(6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-yl)-1,3-benzothiazole;

2-(6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-yl)-1,3-benzoxazole;

1-[6-(5-Methyl-1,2,4-oxadiazol-3-yl)pyridin-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-{1-[(2R)-Butan-2-yl]piperidin-4-yl}-4-[6-(5-propyl-1,2,4-oxadiazol-3-yl)pyridin-2-yl]-1,4-diazepane;

1-[6-(5-Ethyl-1,2,4-oxadiazol-3-yl) pyridine-2-yl]-4-[1-(propan-2-yl)piperidin -4-yl]-1,4-diazepane trihydrochloride;

1-[1-(Propan-2-yl)piperidin-4-yl]-4-[6-(5-propyl-1,2,4-oxadiazol-3-yl)pyridine-2-yl]-1,4-diazepane;

1-[6-(5-Butyl-1,2,4-oxadiazol-3-yl)pyridine-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-{6-[5-(Propan-2-yl)-1,2,4-oxadiazol-3-yl]pyridine-2-yl}-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(5-tert-Butyl-1,2,4-oxadiazol-3-yl)pyridine-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-{6-[5-(2,2-Dimethylpropyl)-1,2,4-oxa diazol-3-yl]pyridine-2-yl}-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)pyridine-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(5-Cyclopentyl-1,2,4-oxadiazol-3-yl)pyridine-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-{6-[5-(Methoxymethyl)-1,2,4-oxa diazol-3-yl]pyridine-2-yl}-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(5-Phenyl-1,2,4-oxadiazol-3-yl)pyridine-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[1-(Propan-2-yl)piperidin-4-yl]-4-{6-[5-(pyridine-2-yl)-1,2,4-oxadiazol-3-yl]pyridine -2-yl}-1,4-diazepane tetrahydrochloride;

1-[1-(Propan-2-yl)piperidin-4-yl]-4-{6-[5-(pyridine-3-yl)-1,2,4-oxadiazol-3-yl]pyridine-2-yl}-1,4-diazepane tetrahydrochloride;

1-[1-(Propan-2-yl)piperidin-4-yl]-4-{6-[5-(pyridine-4-yl)-1,2,4-oxadiazol-3-yl]pyridine-2-yl}-1,4-diazepane tetrahydrochloride;

1-[6-(2-Methyl-2H-1,2,3,4-tetrazol-5-yl)pyridin-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)pyridin-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(3-Phenyl-1,2,4-oxadiazol-5-yl)pyridin-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(5-Butyl-1,3-oxazol-2-yl)pyridin-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(5-Cyclopropyl-1,3,4-oxadiazol-2-yl)pyridin-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(4-Methyl-1H-pyrazol-3-yl)pyridin-2-yl]-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

N-(Cyclopropylmethyl)-6-{7-methyl-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

6-{7,7-Dihydrogenio-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridine-4-yl)pyridine-2-carboxamide;

6-(4-{1-[(2R)-Butan-2-yl]piperidin-4-yl}-7,7-dihydrogenio-1,4-diazepan-1-yl)-N-(pyridine-4-yl)pyridine-2-carboxamide;

6-(4-{1-[(2S)-Butan-2-yl]piperidin-4-yl}-7,7-dihydrogenio-1,4-diazepan-1-yl)-N-(pyridine-4-yl)pyridine-2-carboxamide;

6-(7,7-Dihydrogenio-4-{1-[(2S)-1,1,1-trifluoropropan-2-yl]piperidin-4-yl}-1,4-diazepan-1-yl)-N-(pyridine-4-yl)pyridine-2-carboxamide;

6-[4-(1-Cyclopentylpiperidin-4-yl)-7,7-dihydrogenio-1,4-diazepan-1-yl]-N-(pyridine-4-yl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-7,7-dihydrogenio-1,4-diazepan-1-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{7,7-dihydrogenio-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

6-{6-Methyl-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{6-hydroxy-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{5-methyl-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

6-{4-[3-Fluoro-1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-3-ylmethyl)pyridine-2-carboxamide;

6-{5,5-Dihydrogenio-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-{4-[3-Fluoro-1-(propan-2-yl)piperidin-4-yl]-5,5-dihydrogenio-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-(4-{1-[(2R)-Butan-2-yl]piperidin-4-yl}-5,5-dihydrogenio-1,4-diazepan-1-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-(4-{1-[(2S)-Butan-2-yl]piperidin-4-yl}-5,5-dihydrogenio-1,4-diazepan-1-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-(5,5-Dihydrogenio-4-{1-[(2S)-1,1,1-trifluoropropan-2-yl]piperidin-4-yl}-1,4-diazepan-1-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-[4-(1-Cyclopentylpiperidin-4-yl)-5,5-dihydrogenio-1,4-diazepan-1-yl]-N-(pyridin-4-yl)pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{5,5-dihydrogenio-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

6-{3-Methyl-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{3-methyl-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

6-{5,5-Dihydrogenio-3-methyl-4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-(5,5-Dihydrogenio-3-methyl-4-{1-[(2S)-1,1,1-trifluoropropan-2-yl]piperidin-4-yl}-1,4-diazepan-1-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-{6-[1-(Propan-2-yl)piperidin-4-yl]-3,6-diazabicyclo[3.2.2]nonan-3-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-{6-[3-Fluoro-1-(propan-2-yl)piperidin-4-yl]-3,6-diazabicyclo[3.2.2]nonan-3-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{6-[1-(propan-2-yl)piperidin-4-yl]-3,6-diazabicyclo[3.2.2]nonan-3-yl}pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{3-[1-(propan-2-yl)piperidin-4-yl]-3,6-diazabicyclo[3.2.1]octan-6-yl}pyridine-2-carboxamide;

6-(4-{2-[4-(Propan-2-yl)morpholin-3-yl]ethyl}-1,4-diazepan-1-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-(4-{[(2R)-1-Methyl-4-(propan-2-yl)piperazin-2-yl]methyl}-1,4-diazepan-1-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chloro-4-fluorophenyl)methyl]piperidin-4-yl}-5,5-dihydrogenio-1,4-diazepan-1-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl]piperidin-4-yl}-5,5-dihydrogenio-1,4-diazepan-1-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chloro-4-fluorophenyl)methyl]piperidin-4-yl}-7,7-dihydrogenio-1,4-diazepan-1-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chlorophenyl)methyl] piperidin-4-yl}-5,5-dihydrogenio-3-methyl-1,4-diazepan-1-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chloro-4-fluorophenyl) methyl]piperidin-4-yl}-5,5-dihydrogenio-3-methyl-1,4-diazepan-1-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-(6-{1-[(2-Chlorophenyl)methyl]piperidin-4-yl}-3,6-diazabicyclo[3.2.2]nonan-3-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-(6-{1-[(2-Chloro-4-fluorophenyl)methyl]piperidin-4-yl}-3,6-diazabicyclo[3.2.2]nonan-3-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-{4-[3-Fluoro-1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-{4-[3-Fluoro-1-(propan-2-yl)piperidin-4-yl]-7,7-dihydrogenio-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide;

1-[6-(4-Cyclopropyl-1H-imidazol-2-yl)pyridin-2-yl]-4-[3-fluoro-1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-[6-(4-Cyclopropyl-5-methyl-1H-imidazol-2-yl)pyridin-2-yl]-4-[3-fluoro-1-(propan-2-yl)piperidin-4-yl]-1,4-diazepane;

1-(1-Cyclopentyl-3-fluoropiperidin-4-yl)-4-[6-(4-cyclopropyl-5-methyl-1H-imidazol-2-yl)pyridin-2-yl]-1,4-diazepane;

6-{4-[2-Methyl-1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-3-ylmethyl)pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{4-[(3R)-3-hydroxy-1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{10-[1-(propan-2-yl)piperidin-4-yl]-3,10-diazabicyclo[4.3.1]decan-3-yl}pyridine-2-carboxamide;

6-(10-{1-[(2-Chlorophenyl)methyl]piperidin-4-yl}-3,10-diazabicyclo[4.3.1]decan-3-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide;

1-(6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridin-2-yl)butan-1-one;

2-Phenyl-1-(6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}pyridin-2-yl)ethan-1-one;

6-({1-[1-(Propan-2-yl)azepan-4-yl]piperidin-4-yl}oxy)-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-({1-[1-(Propan-2-yl)piperidin-4-yl]piperidin-3-yl}amino)-N-(pyridin-4-yl)pyridine-2-carboxamide;

(3R)-1-[6-(4-Cyclopropyl-1H-imidazol-2-yl)pyridin-2-yl]-N-{[1-(propan-2-yl)piperidin-4-yl]methyl}pyrrolidin-3-amine;

(3R)-N-{[(3S)-1-Cyclopentylpyrrolidin-3-yl]methyl}-1-[6-(4-cyclopropyl-5-methyl-1H-imidazol-2-yl)pyridin-2-yl]pyrrolidin-3-amine;

(3R)-N-{[(3R)-1-Cyclopentylpyrrolidin-3-yl]methyl}-1-[6-(4-cyclopropyl-5-methyl-1H-imidazol-2-yl)pyridin-2-yl]pyrrolidin-3-amine;

6-[(3R)-3-({[(3S)-1-Cyclopentylpyrrolidin-3-yl]methyl}amino)pyrrolidin-1-yl]-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-[(3R)-3-({[(3R)-1-Cyclopentylpyrrolidin-3-yl]methyl}amino)pyrrolidin-1-yl]-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-[(3R)-3-{[(1-Cyclopentylpiperidin-4-yl)methyl]amino}pyrrolidin-1-yl]-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-(4-{1-[(2-Methylphenyl)methyl]azepan-4-yl}piperazin-1-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-(4-{1-[(2-Chloro-4-fluorophenyl)methyl]azepan-4-yl}piperazin-1-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide;

6-{4-[1-(Propan-2-yl)azepan-4-yl]piperazin-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide;

4-{4-[6-(5-Cyclopropyl-4-methyl-1H-imidazol-2-yl)pyridin-2-yl]piperazin-1-yl}-1-(propan-2-yl)azepane;

6-(4-{[(2R)-4-(Propan-2-yl)morpholin-2-yl]methyl}-1,4-diazepan-1-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide;

1-Cyclopentyl-4-{4-[6-(5-cyclopropyl-4-methyl-1H-imidazol-2-yl)pyridin-2-yl]piperazin-1-yl}azepane;

6-(4-{[1-(Propan-2-yl)piperidin-4-yl]amino}piperidin-1-yl)-N-(pyridin-4-yl)pyridine-2-carboxamide;

N-Butyl-6-(4-{[4-(propan-2-yl)morpholin-2-yl]methyl}-1,4-diazepan-1-yl)pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{4-[3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

N-(Cyclopropylmethyl)-6-{4-[3-(3,3-difluoropyrrolidin-1-yl)propyl]-1,4-diazepan-1-yl}pyridine-2-carboxamide;

6-{4-[2-Hydroxy-3-(propan-2-ylamino)propyl]-1,4-diazepan-1-yl}-N-(pyridin-3-ylmethyl)pyridine-2-carboxamide;

1-[6-(4-Cyclopropyl-1H-imidazol-2-yl)pyridin-2-yl]-4-[4-(pyrrolidin-1-yl)cyclohexyl]-1,4-diazepane;

6-[4-(4-tert-Butylcyclohexyl)-1,4-diazepan-1-yl]-N-(pyridin-3-ylmethyl)pyridine-2-carboxamide;

N-(Pyridin-4-yl)-6-(4-{4-[2-(trifluoromethyl)pyrrolidin-1-yl]cyclohexyl}-1,4-diazepan-1-yl)pyridine-2-carboxamide;

6-[4-(3-{[(2-Chlorophenyl)methyl]amino}propyl)-1,4-diazepan-1-yl]-N-(cyclopropylmethyl)pyridine-2-carboxamide;
6-(4-{1-[(2-Chlorophenyl)methyl]piperidin-4-yl}-1,4-diazepan-1-yl)pyridine-2-carbonitrile;
[6-(4-{1-[(2-Chlorophenyl)methyl]piperidin-4-yl}-1,4-diazepan-1-yl)pyridin-2-yl]methanol;
1-{1-[(2-Chlorophenyl)methyl]piperidin-4-yl}-4-(pyridin-2-yl)-1,4-diazepane;
1-{1-[(2-Chlorophenyl)methyl]piperidin-4-yl}-4-(6-methylpyridin-2-yl)-1,4-diazepane;
1-{1-[(2-Chlorophenyl)methyl]piperidin-4-yl}-4-(5-methylpyridin-2-yl)-1,4-diazepane;
1-{1-[(2-Chlorophenyl)methyl]piperidin-4-yl}-4-(4-methylpyridin-2-yl)-1,4-diazepane;
2-(4-{1-[(2-Chlorophenyl)methyl]piperidin-4-yl}-1,4-diazepan-1-yl)-N-(cyclopropylmethyl)-1,3-thiazole-4-carboxamide;
2-(4-{1-[(2-Chlorophenyl)methyl]piperidin-4-yl}-1,4-diazepan-1-yl)-N-[3-(1H-imidazol-1-yl)propyl]-6-methylpyrimidine-4-carboxamide;
1-{1-[(2-Chlorophenyl)methyl]piperidin-4-yl}-4-(1,3-thiazol-2-yl)-1,4-diazepane;
6-(4-{1-[(2-Chlorophenyl)methyl]piperidin-4-yl}-1,4-diazepan-1-yl)-N-(cyclopropylmethyl)-4-methylpyridine-2-carboxamide;
2-(4-{1-[(2-chlorophenyl)methyl]piperidin-4-yl}-1,4-diazepan-1-yl)-N-(cyclopropylmethyl)pyridine-4-carboxamide;
6-(4-{1-[(2-Chlorophenyl)methyl]piperidin-4-yl}-1,4-diazepan-1-yl)-N-(cyclopropylmethyl)-5-methoxypyridine-2-carboxamide;
and pharmaceutically acceptable salts thereof.

17. A pharmaceutical composition comprising a compound as claimed in any of the preceding claims, together with one or more pharmaceutically acceptable carriers and/or excipients.

18. The use of a compound as claimed in any of claims 1 to 16 in the preparation of a ~~composition~~ medicament for treatment of a condition responsive to the reduction of CXCR4 mediated activity.

~~19. A method of treatment of a condition responsive to the reduction of CXCR4 mediated activity in a subject, comprising administrating to the subject an amount of a compound as claimed in any of claims 1 to 16 effective to reduce such CXCR4 mediated activity.~~

~~20~~19. The use as claimed in claim 18 ~~or a method as claimed in claim 19,~~ wherein the condition is cancer including cancers of the haematopoietic system such as multiple myeloma

and non-Hodgkin's lymphoma, non-small cell lung, breast and neuroblastoma, cancer metastasis, HIV/AIDS, neuropathy, HIV related neuropathy, pain, inflammation, brain inflammation, neurodegeration, cognitive degeneration, diabetic retinopathy, age related macular degeneration, retinal neo-vascularisation, and viral infections.

~~21. The use of a compound as claimed in any of claims 1 to 16 in an apheresis procedure for promoting release and mobilisation of stem cells, including haematopoietic and non-haematopoietic stem cells and progenitor stem cells prior to harvesting.~~

~~22. The use of a compound as claimed in any of claims 1 to 16 and GCSF in an apheresis procedure for promoting release and mobilisation of stem cells, including haematopoietic and non-haematopoietic stem cells and progenitor stem cells prior to harvesting.~~

~~23. The use according to claim 21 or 22 wherein the said apheresis procedure is implemented prior to treatment of a subject by chemotherapy or radiotherapy, for reducing chemotherapy- or radiotherapy-induced leukopenia.~~

~~24. The use according to claim 20 wherein the said compound is administered as an adjunct to chemotherapy or radiotherapy to sensitize tumours to such chemotherapy or radiotherapy.~~

~~25~~20. The use according to claim 18 for inhibition of neo-vascularisation, angiogenesis, or vasculogenesis.